Assembly Biosciences, Inc. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
Assembly Biosciences, Inc. (ASMB) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of $56.14 thousand for the 3-month period ending 2018-09-30, per its 10-Q filed 2018-11-08.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2018-11-08
- Assembly Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2018-09-30 was $56.14K, a 47.78% increase year-over-year.
- Assembly Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2018-06-30 was $36.31K, a 80.20% decline year-over-year.
- Assembly Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2017-12-31 was -$72.71K, a 116.64% decline year-over-year.
- Assembly Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2017-09-30 was $37.99K.
- Assembly Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2017 was $148.65K, a 65.99% decline from fiscal 2016.
- Assembly Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2016 was $437.06K.
- Assembly Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2015 was $0.00.
- Assembly Biosciences, Inc. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2014 was $0.00.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 9 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2018-09-30 | $56.14K 10-Q · filed 2018-11-08 | $92.45K derived: sum of 2 quarters · filed 2018-11-08 | $56.14K 10-Q · filed 2018-11-08 | |
| 2018-06-30 | $36.31K 10-Q · filed 2018-08-08 | $36.31K 10-Q · filed 2018-08-08 | ||
| 2017-12-31 | -$72.71K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$34.73K derived: sum of 2 quarters · filed 2018-11-08 | $148.65K derived: sum of 3 quarters · filed 2018-11-08 | $148.65K 10-K · filed 2018-03-08 |
| 2017-09-30 | $37.99K 10-Q · filed 2018-11-08 | $221.36K derived: sum of 2 quarters · filed 2018-11-08 | $221.36K 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $183.37K 10-Q · filed 2018-08-08 | $183.37K 10-Q · filed 2018-08-08 | ||
| 2016-12-31 | $437.06K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $437.06K derived: sum of 2 quarters · filed 2018-03-08 | $437.06K derived: sum of 3 quarters · filed 2018-03-08 | $437.06K 10-K · filed 2018-03-08 |
| 2016-09-30 | $0.00 10-Q · filed 2017-11-01 | $0.00 derived: sum of 2 quarters · filed 2017-11-01 | $0.00 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $0.00 10-Q · filed 2017-08-09 | $0.00 10-Q · filed 2017-08-09 | ||
| 2015-12-31 | $0.00 10-K · filed 2018-03-08 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |